Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
Microvasc Res. 2022 Jul;142:104366. doi: 10.1016/j.mvr.2022.104366. Epub 2022 Mar 26.
Digital ulcers (DUs) are one of the main causes of disability among systemic sclerosis (SSc) patients. The inflammation plays a crucial role in mediating the pathophysiological process underlying SSc. Objective of this study was to evaluate Maresin1 (MaR1) serum levels in SSc patients and in healthy controls (HC). Secondary aims were to evaluate the relationship between MaR and diseases variables and to assess the predictive role of MaR1 in the development of new digital ulcers (DUs) during 18 weeks follow-up.
MaR1 serum level was evaluated in 55 SSc patients and 24 HC. In SSc patients, clinical assessment was performed at baseline and after 18 week follow-up by the same-blinded observer on serum MaR1 levels.
MaR1 was significantly lower in SSc patients than in HC [367 pg/ml (IQR 304-468.3 pg/ml) vs 467.7 pg/ml (IQR 422-522 pg/ml), p < 0.001]. During follow-up, six patients (10.9%) developed DUs. MaR1 was higher in SSc patients with new DUs than in patients without new DUs [518.2 pg/ml (IQR 468.2-596.5 pg/ml) vs 355 pg/ml (IQR 299.8-444.7 pg/ml), p < 0.01]. Free survival from new DUs is significantly lower in SSc patients with increased MaR1 serum level than in SSc patient with normal MaR1 serum level. In multivariate analysis, serum level of MaR1 > 393.2 pg/ml is a predictive marker for new DUs.
In SSc patients, MaR1 is reduced compared to HC and it is a predictive marker of new DUs.
手指溃疡（DU）是系统性硬化症（SSc）患者致残的主要原因之一。炎症在介导 SSc 的病理生理过程中起着关键作用。本研究旨在评估 SSc 患者和健康对照者（HC）的maresin1（MaR1）血清水平。次要目的是评估 MaR 与疾病变量之间的关系，并评估 MaR1 在 18 周随访期间预测新出现手指溃疡（DU）的作用。
评估了 55 例 SSc 患者和 24 例 HC 的 MaR1 血清水平。在 SSc 患者中，由同一位盲法观察者在基线和 18 周随访时进行临床评估，并检测血清 MaR1 水平。
SSc 患者的 MaR1 明显低于 HC [367pg/ml（IQR 304-468.3pg/ml）比 467.7pg/ml（IQR 422-522pg/ml），p<0.001]。随访期间，有 6 例患者（10.9%）出现 DU。有新 DU 的 SSc 患者的 MaR1 高于无新 DU 的患者[518.2pg/ml（IQR 468.2-596.5pg/ml）比 355pg/ml（IQR 299.8-444.7pg/ml），p<0.01]。MaR1 血清水平升高的 SSc 患者新 DU 的无复发生存率明显低于 MaR1 血清水平正常的 SSc 患者。多变量分析显示，MaR1 血清水平>393.2pg/ml 是新 DU 的预测标志物。
在 SSc 患者中，MaR1 低于 HC，是新 DU 的预测标志物。
